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Abstract
Introduction: Post cardiac surgery vasodilatation (PCSV) is possibly related to a vasopressin deficiency that could
relate to chronic stimulation of adeno-hypophysis. To assess vasopressin system activation, a perioperative course
of copeptin and vasopressin plasma concentrations were studied in consecutive patients operated on for cardiac
surgery.
Methods: Sixty-four consecutive patients scheduled for elective cardiac surgery with cardiopulmonary bypass were
studied. Hemodynamic, laboratory and clinical data were recorded before and during cardiopulmonary bypass, and
at the eighth postoperative hour (H8). At the same time, blood was withdrawn to determine plasma
concentrations of arginine vasopressin (AVP, radioimmunoassay) and copeptin (immunoluminometric assay). PCSV
was defined as mean arterial blood pressure < 60 mmHg with cardiac index ≥ 2.2 l/min/m
2, and was treated with
norepinephrine to restore mean blood pressure > 60 mmHg. Patients with PCSV were compared with the other
patients (controls). Student’s t test, Fisher’s exact test, or nonparametric tests (Mann-Whitney, Wilcoxon) were used
when appropriate. Correlation between AVP and copeptin was evaluated and receiver-operator characteristic
analysis assessed the utility of preoperative copeptin to distinguish between controls and PCSV patients.
Results: Patients who experienced PCSV had significantly higher copeptin plasma concentration before
cardiopulmonary bypass (P < 0.001) but lower AVP concentrations at H8 (P < 0.01) than controls. PCSV patients
had preoperative hyponatremia and decreased left ventricle ejection fraction, and experienced more complex
surgery (redo). The area under the receiver-operator characteristic curve of preoperative copeptin concentration
was 0.86 ± 0.04 (95% confidence interval = 0.78 to 0.94; P < 0.001). The best predictive value for preoperative
copeptin plasma concentration was 9.43 pmol/l with a sensitivity of 90% and a specificity of 77%.
Conclusions: High preoperative copeptin plasma concentration is predictive of PSCV and suggests an activation of
the AVP system before surgery that may facilitate depletion of endogenous AVP stores and a relative AVP deficit
after surgery.
Introduction
Severe postoperative cardiovascular failure occurs in 3
to 5% of patients undergoing cardiac surgery using car-
diopulmonary bypass (CPB) [1,2]. In some cases, a post
cardiotomy vasodilatory shock characterized by a
decreased vascular tone has been reported that might be
explained by inadequate plasma concentrations of the
vasoconstrictor hormone arginine vasopressin (AVP)
[3-5]. Accordingly, first clinical reports showed benefi-
cial effects of AVP treatment in cardiac surgery patients
with severe vasodilatory shock [6,7] that correlates with
results observed in septic shock where a deficiency in
vasopressin has been described [8,9]. However, why
some patients are prone to develop a deficiency in vaso-
pressin after cardiac surgery, and whether postoperative
vasodilatation without shock (vasoplegia) is associated
with vasopressin deficiency, remain unclear.
Generation of copeptin correlates with the release of
vasopressin, since both are derived from the same precur-
sor. Furthermore, the stability of the precursor protein
was found to be high and fully suitable for routine pur-
poses. Copeptin is therefore easier to measure than vaso-
pressin, and could be used as a marker of vasopressin
release [5,10]. High copeptin concentration has been
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infarction [11,12]. There are robust data showing that
vasopressin is related to heart failure severity and outcome
[13]. A prognosis-predictive value of copeptin has also
been shown in critically ill patients [10,11,14,15], in coron-
ary artery disease [16] and in advanced heart failure [17].
We hypothesized that patients who develop post car-
diac surgery vasodilation (PCSV) may have an activation
of the vasopressin system before surgery that favors a
relative deficit in vasopressin after surgery. We have
analyzed the kinetics of plasma concentrations of copep-
tin and AVP before, during and just after cardiac sur-
gery in patients undergoing elective uncomplicated
cardiac surgery, and compared patients with PCVS syn-
drome with the other patients.
Materials and methods
Patient selection and management
The observational study was designed to collect perio-
perative data from consecutive patients operated on for
elective cardiac surgery with CPB until a total of 10
patients experiencing PCSV (see definition below) had
been included. Patients suffering from chronic renal fail-
ure and under dialysis, and patients who underwent
complicated surgical course (significant bleeding requir-
ing reoperation, low cardiac output requiring high ino-
trope dose exceeding dobutamine > 10 μg/kg/minute or
any dose of adrenaline and/or mechanical circulatory
assistance) were not included. Comprehensive preopera-
tive data were collected from cardiac and medical his-
tories for all patients. All patients gave written informed
consent for collecting their perioperative records, and
blood samples for AVP and copeptin measurements
were obtained from plasma processed for routine biolo-
gical measurements. The protocol met the criteria of a
noninterventional study design as defined by French law
and has been approved by the Institutional Review
Board of Centre Hospitalier Universitaire de Nîmes.
The usual cardiac treatment was maintained until the
day before surgery. Perioperative management (anesthesia,
CPB, and cardioplegia) is standardized for all patients.
General anesthesia was induced and maintained with
titrated propofol and sufentanil. Cisatracurium was used
to facilitate endotracheal intubation. After tracheal intuba-
tion, ventilation was controlled to ensure normal blood
gases using an inspired oxygen concentration of 50% (oxy-
gen-air mixture) before CPB, and 100% oxygen after
separation from bypass. In all patients, a peripheral vein
was cannulated before anesthesia, and an arterial radial
catheter was inserted after induction of anesthesia for con-
tinuous monitoring of mean arterial pressure (MAP).
Before CPB, hypertension and hypotension were defined
as an increase or a decrease in MAP of ≥ 20% from base-
line (preinduction MAP), respectively. Hypertension was
treated with additional doses of sufentanil. Hypotension
was treated with rapid intravenous administration of lac-
tated Ringer’s solution. Ephedrine (3 mg bolus) could be
used when MAP was ≤ 60 mmHg. After aortic and right
atrium cannulation, CPB was instituted with a membrane
oxygenator primed with 1.5 l crystalloid, and body tem-
perature was maintained at 34 to 36°C. After aortic cross-
clamping, a hyperkalemic blood cardioplegic solution was
infused into the aortic root of the aorta until myocardial
arrest. A nonpulsatile pump flow rate was maintained
between 2.2 and 2.6 l/min/m
2, provided the mixed venous
oxygen saturation monitored on the pump machine
exceeded 60%. After completion of the surgical procedure,
patients were weaned from CPB when a rectal tempera-
ture of 36°C had been reached.
In the ICU, inotropic support (dobutamine) was used
in order to obtain a cardiac index output ≥ 2.2 l/min/m
2
as assessed by thermodilution (pulmonary catheter) or
echocardiography (aortic flow measured by pulsed Dop-
pler time velocity integral). Hypotension (MAP ≤ 60
mmHg) without cardiogenic shock features (all patients
had cardiac index > 2.2 l/min/m
2) defined PCSV, and
was treated with continuous intravenous administration
of norepinephrine in order to restore MAP > 60 mmHg.
Weaning from the ventilator was started during emer-
gence of anesthesia, and extubation occurred when stable
hemodynamics and normothermia had been maintained
for ≥ 1 hour under propofol infusion; repeated boluses of
morphine were used to keep patients pain-free.
Data collection
For all patients, demographic data, past medical history,
chronic intake of cardiac drugs or drugs with possible
interference with sodium balance (diuretics), preoperative
ejection fraction, type of surgical intervention, and the
aortic cross-clamp and surgery times were documented.
The MAP and heart rate were monitored continu-
ously. Laboratory parameters (hemoglobin, serum osmo-
larity, creatinine, electrolytes, arterial lactate, and arterial
blood gas analysis), urine output, administration of
ephedrine, diuretics, dobutamine or norepinephrine, and
the need for volume loading were recorded during sur-
gery and during the first 8 postoperative hours.
Blood samples were obtained from routine blood with-
drawals before CPB (T0), during CPB and after surgery,
at the eighth postoperative hour (H8), without extra
blood subtraction. These samples were used for AVP
and copeptin measurements.
Measurement of AVP and copeptin plasma concentrations
Blinded frozen plasma samples were transferred to the
endocrinology laboratories. For measurement of AVP, 1
ml ethylenediamine tetraacetic acid plasma was extracted
with 4 ml ethanol, evaporated, and then reconstituted in 1
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extract was assayed using a radioimmunoassay (Bühlman
Laboratories AG, Schonenbuch, Switzerland). The AVP
assay standard calibration curve ranges from 1.25 to 80
pg/ml with a minimum quantization limit of 0.75 pg/ml.
The intra-assay and inter-assay variation is 6.0% and 9.9%,
respectively. Only when test results lay outside the clini-
cally expected range (< 1.25 pg/ml or > 80 pg/ml) were
measurements repeated to confirm the results. All other
measurements were performed once.
Copeptin plasma concentrations were determined
using a sandwich immunoluminometric assay (B.R.A.H.
M.S. Copeptin LIA; Thermo Fisher Scientific, Hennigs-
dorf/Berlin, Germany). The lower detection limit was
0.4 pmol/l and the functional assay sensitivity (20%
inter-assay coefficient of variation) was < 1 pmol/l.
Statistical analysis
The 10 patients with PCSV were compared with the
other patients (control group). For statistical analysis, the
SPSS software program (Version SigmatStat 3.0; SPSS
Inc., San Jose, CAL, USA) and XLSTAT (version
2011.3.01; Addinsoft, Paris, France) were used. Normality
distribution was assessed by a Kolmonorov-Smirnov test.
Most variables showed deviation from normality and
were analyzed with nonparametric tests (Mann-Whitney
or Wilcoxon tests). Few variables showed a normal distri-
bution and were analyzed with Student’s t tests, but all
data are expressed as the median (25th to 75th percen-
tiles) to simplify presentation. A Fisher’s exact test was
performed to analyze proportions and rates. For multiple
comparisons (n = 3 for AVP or copeptin measurements),
a Friedman repeated-measure analysis of variance with a
Dunn method was used within groups and a Bonferroni
correction was used for comparison between groups (sta-
tistical significance was then assumed if P ≤ 0.016). A
Spearman rank-order correlation test was performed to
assess the correlation between AVP and copeptin plasma
concentrations in all study patients.
Receiver-operator characteristic analysis (area under
the curve, with 95% confidence interval) was calculated
to assess the utility of preoperative copeptin to distin-
guish between controls and PCSV patients. We consid-
ered P ≤ 0.05 as statistically significant.
Results
Sixty-four patients were included within 2 months, of
which 10 were treated with norepinephrine in the ICU.
Preoperative data for the two groups are summarized in
Table 1. Patients who experienced PCSV were more
Table 1 Preoperative characteristics
PCSV patients (n = 10) Controls (n = 54) P value
Age (years) 70 (57 to 77) 67 (60 to 76) 0.71
Male (%) 7 (70) 36 (67) 1.00
Body mass index 25.7 (23.1 to 28.6) 26.3 (24.3 to 28.0) 0.62
Preoperative status
LVEF (%) 50 (30 to 60) 60 (50 to 70) 0.03
Urea (mmol/l) 7.3 (6.4 to 15.2) 7.3 (5.9 to 10.8) 0.38
Na
+ (mmol/l) 137 (134 to 139) 140 (138 to 141) 0.01
Osmolarity (mOsmol/l) 292 (284 to 296) 294 (290 to 298) 0.06
Hemoglobin (g/dl) 12.3 (10.1 to 15.0) 13.2 (11.7 to 14.6) 0.32
Platelets (10
9/l) 196.5 (131 to 241) 219.5 (181 to 252) 0.10
Comorbidities
Hypertension (%) 5 (50) 24 (44) 0.75
Diabetes (%) 4 (40) 7 (13) 0.06
Euroscore 9.5 (6 to 14) 6 (5 to 8) 0.02
Preoperative treatments
Beta-blocker (%) 4 (40) 28 (52) 0.73
ACE inhibitor or sartan (%) 5 (50) 37 (69) 0.29
Calcium antagonist (%) 1 (10) 11 (20) 0.67
Diuretic (%) 9 (90) 26 (48) 0.02
Statin (%) 6 (60) 32 (59) 1.00
AVP and copeptin
AVP (pmol/ml) 4.3 (1.4 to 6.3) 2.1 (0.9 to 5.1) 0.34
Copeptin (pmol/l) 30.1 (9.8 to 69) 4.8 (3.0 to 9.2) < 0.001
Data expressed as median (25th to 75th percentiles) or number (%). ACE, angiotensin-converting enzyme inhibitor; AVP, arginine vasopressin; LVEF, left ventricle
ejection fraction; PCSV, post cardiac surgery vasodilatation.
Colson et al. Critical Care 2011, 15:R255
http://ccforum.com/content/15/5/R255
Page 3 of 8often in New York Heart Association functional class IV
(50% vs. 7.4%, respectively; P =0 . 0 1 ) ,h a dl o w e rp r e o -
perative left ventricle ejection fraction and natremia,
were more frequently treated with diuretics, and had a
higher copeptin levels before CPB than controls. The
area under the receiver-operator characteristic curve for
preoperative copeptin concentration was 0.86 ± 0.04
(95% confidence interval = 0.78 to 0.94; P < 0.001) (Fig-
ure 1). The best predictive value for preoperative copep-
tin plasma concentration was 9.43 pmol/l with a
sensitivity of 90% and a specificity of 77% (positive pre-
dictive value = 43%, negative predictive value = 98%).
Surgery procedure details are reported in Table 2.
PCSV patients had longer CPB (191 minutes (150 to
280) vs. 103 minutes (87 to 159), P < 0.001) and clamp-
ing times (75.5 minutes (58 to 104) vs. 138.5 minutes
(115 to 192), P < 0.001) than controls, but no significant
hemodynamic differences during surgery and CPB.
However, they more often needed inotropic support
with moderate doses of dobutamine to achieve adequate
cardiac output after CPB weaning (8/10 vs. 4/54, P <
0.001) (Table 2). The AVP plasma concentration
increased significantly between T0 and CPB in controls
(P < 0.016) but not in PCSV patients. Copeptin plasma
levels did not increase significantly in either group
between T0 and CPB but were significantly higher in
the PCSV patients than in controls.
After surgery, PCSV patients were treated with a mod-
erate dose of norepinephrine (range doses from 0.1 to 1.1
mg/hour). The PCSV patients have a longer extubation
time (24 hours (16 to 48) vs. 6 hours (4 to 9.25), P <
0.001) and were more frequently treated with dobuta-
mine (range doses from 0 to 10 μg/kg/minute) than
other patients (Table 3). The total fluid volume load dur-
ing surgery and in the first 8 postoperative hours was not
significantly different between PCSV patients and other
patients (3,250 ml (2,750 to 4,000) vs. 3,000 ml (2,500 to
4,000), respectively; P =0 . 4 3 ) .W h i l eP C S Vp a t i e n t s
remained intubated for a longer time than other patients,
the propofol cumulative dose over the first 8 hours was
not significantly different from other patients (350 mg
(380 to 520) vs. 215 mg (155 to 375), respectively; P =
0.16). The AVP plasma concentration increase was statis-
tically significant between T0 and H8 and between CPB
and H8 in the control group (P < 0.001), and between T0
a n dH 8i nt h eP C S Vg r o u p( P =0 . 0 1 ) ,b u tw a ss i g n i f i -
cantly lower at H8 in PCSV patients than in controls
(Table 3). The plasma copeptin concentration increased
significantly between T0 and H8 and between CPB and
H8 in both the control and PCSV groups (P < 0.001).
All patients were discharged from the hospital within
a few days without serious complications.
The Spearman rank-order correlation test to assess
the relation between AVP and copeptin plasma concen-
trations was performed on the base of 191 pairs. The
correlation is significant (r = 0.76, P < 0.001) (Figure 2).
Discussion
The present study shows that preoperative copeptin
plasma concentration is predictive of PCSV. Increased
preoperative copeptin could be a marker of vasopressin
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Figure 1 Receiver-operator characteristic analysis of preoperative copeptin. Receiver-operator characteristic analysis (area under the curve
with 95% confidence interval) to assess the utility of preoperative copeptin to distinguish between controls and post cardiac surgery
vasodilatation patients. Receiver-operator characteristic area under the curve was 0.86 ± 0.04 (95% confidence interval = 0.78 to 0.94; P < 0.001).
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system deficiency after surgery.
Our results are in agreement with previous publica-
tions where low AVP plasma concentrations have been
observed in refractory vasodilatory shock when com-
pared with cardiogenic shock shortly after CPB for car-
diac surgery [6]. These results extend the likelihood of a
vasopressin deficiency to vasodilatation without shock.
We did not observe norepinephrine resistance in this
small series of patients; however, the so-called catecho-
lamine resistance varies widely between studies and
between patients within studies [4,6,7]. As an example,
in a series of 40 patients treated with vasopressin for
vasodilatory shock the mean administered dose of nore-
pinephrine was 14.4 ± 13.7 μg/minute [6]. The wide
standard deviation suggests some patients were consid-
ered catecholamine resistant even when a rather small
dose of norepinephrine was infused.
The AVP plasma concentration increase during car-
diac surgery performed under CPB has been described
for years [18,19]. The AVP peak has been related to
arterial hypotension during CPB and to postoperative
stimulation of AVP release byi n f l a m m a t o r ym e d i a t o r s
[20,21]. In the present study, AVP and copeptin plasma
Table 2 Intraoperative data
PCSV patients (n = 10) Controls (n = 54) P value
Surgery
Ascending aorta (%) 2 (20) 7 (13) 0.63
Coronary artery bypass graft (%) 0 (0) 21 (39) 0.02
Valve (%) 8 (80) 26 (48) 0.09
Redo (%) 3 (30) 3 (6) 0.04
Fluid administration
Crystalloids (ml) 20,000 (1,500 to 3,000) 2,000 (2,000 to 25,000) 0.97
Colloids (ml) 0 (0 to 500) 500 (0 to 500) 0.73
Transfusion (packed red cell units) 2 (0 to 5) 0 (0 to 2) 0.10
Perioperative treatments
Number of patients treated with ephedrine (%) 4 (40) 23 (42.6) 1.00
Dobutamine total dose (mg) 35 (25 to 60) 0 (0 to 0) 0.001
Furosemid total dose (mg) 5 (0 to 10) 0 (0 to 0) 0.161
AVP and copeptin
AVP during CPB (pmol/l) 9.3 (1.3 to 11.4) 6.4 (1.8 to 18.4) 0.78
Copeptin during CPB (pmol/l) 50.8 (35.9 to 63.4) 9.4 (3.77 to 36.3) 0.02
Data expressed as the median (25th to 75th percentiles). AVP, arginine-vasopressin; CPB, cardiopulmonary bypass; PCSV, post cardiac surgery vasodilatation.
Table 3 Postoperative data
PCSV patients (n = 10) Controls (n = 54) P value
Hemodynamic treatments
Dobutamine dose over first 8 hours (μg/kg/minute) 5.8 (5.0 to 6.9) 0 (0 to 0) 0.001
Norepinephrine dose over first 8 hours (mg/hour) 3.5 (1 to 7) 0 0.001
Fluid administration
Crystalloid dose over 8 hours (ml) 0 (0 to 500) 0 (0 to 0) 0.43
Colloid dose over 8 hours (ml) 500 (250 to 500) 500 (0 to 500) 0.50
Transfusion (packed red cell units) 0 (0 to 2) 0 (0 to 0) 0.32
Biology
Lactate H0 (mmol/l) 1.8 (1.5 to 2.1) 1.4 (1 to 2) 0.16
Lactate H8 (mmol/l) 2.25 (1.5 to 2.6) 1.45(1.1 to 2.2) 0.06
Osmolarity H8 (mOsmol/l) 288 (284 to 293) 288 (284 to 293) 0.89
Platelets (10
9/l) 81.5 (63 to 135) 124 (103 to 146) 0.06
Hemoglobin concentration (g/dl) 9.5 (8.8 to 10.6) 10.3 (9.5 to 11.4) 0.16
AVP and copeptin
AVP H8 (pmol/l) 16.9 (12.9 to 24.5) 42.6 (23.7 to 79) 0.01
Copeptin H8 (pmol/l) 137.5 (118 to 193) 208 (121 to 300) 0.23
Data expressed as the median (25th to 75th percentiles). AVP, arginine vasopressin; H0, arrival in the ICU; H8, eighth postoperative hour; PCSV, post cardiac
surgery vasodilatation.
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AVP response to cardiac surgery resembles the post-
operative course of other stress hormones, so higher
AVP plasma concentrations would have been expected
in patients with hypotension when compared with
patients with normal blood pressure [6,22]. Although
more patients in the norepinephrine-treated group were
receiving dobutamine, which may have contributed to
the vasodilatation, AVP levels are lower in these patients
than expected in cases of significant hypotension (MAP
< 60 mmHg) [6]. Similar inadequacy between plasma
concentrations of AVP and low blood pressure has been
documented in septic shock, where there is some evi-
dence that depletion of endogenous AVP stores follows
vigorous stimulation of AVP release from the neurohy-
pophysis [7,8,23].
A chronic stimulation of the vasopressin system that
may contribute to AVP store depletion has been demon-
strated in chronic heart failure [11-13]. High copeptin
plasma levels have been observed in chronic heart fail-
ure and acute myocardial infarction; vasopressin produc-
tion is related to the severity of heart failure [11-13].
Increased plasma levels of copeptin have been linked to
excess mortality in chronic heart failure, and this link is
observed irrespective of the clinical signs of severity of
the disease. In the present study, PCSV patients had
lower preoperative left ventricle ejection fraction and
hyponatremia, both relevant markers of heart failure.
Copeptin plasma concentration is higher in these
patients than in controls; copeptin plasma levels are in
the range of values already reported in New York Heart
Association functional class III and IV patients [11].
Interestingly, the median preoperative copeptin value
with a significant prognostic value (9.43 pmol/l) is dou-
ble the median copeptin value of the normal population,
as reported in the literature [12], and also is similar to
the control population of the study. The lower response
of vasopressin after surgeryw h i l et h ep r e o p e r a t i v e
copeptin concentration was increased may be thus
accounted for by a depletion of endogenous AVP stores,
as a result of sustained preoperative vasopressin system
stimulation.
Although significant, the correlation between AVP and
copeptin appears rather weak (r = 0.76), probably
because direct determination of AVP is liable to gener-
ate inconsistencies (short half-life of AVP, 90% of which
bound to blood platelets, and temperature sensitivity of
the blood sample). These effects have hindered the use
of AVP dosage in routine diagnostics. The correlation
between AVP and copeptin plasma concentration
observed in the study is nevertheless similar to that
reported in other studies [5,14]. Generation of copeptin
correlates with the release of vasopressin, since they are
derived from the same precursor. Copeptin is a stable
fragment of the AVP precursor pre-pro-vasopressin and
is released together with AVP in a 1:1 stochiometric
pattern [24]. The advantages of copeptin are its long sta-
bility and that it can be quickly and reliably measured in
unprocessed plasma or serum. Copeptin may therefore
be used as a surrogate parameter of vasopressin system
stimulation [25].
The small number of patients in the present study is a
limitation that should be taken into account for inter-
preting negative results such as the absence of difference
in copeptin plasma concentration between PCSV
patients and the others after surgery during the AVP
peak. The similar copeptin and AVP variations and a
marked increase in copeptin after surgery in controls
when compared with PCSV patients, however, are in
agreement with AVP kinetics, and eventually AVP defi-
ciency in PCVS patients. The plasma AVP measurement
is known to be affected by platelet counts [5]. Neverthe-
less, the significant difference in AVP plasma concentra-
tion between the two groups after surgery (twofold
higher in untreated patients than in PCSV patients) can-
not be accounted for by the slight difference in platelet
counts. Moreover, the increase in median copeptin
plasma concentration after surgery, which is not influ-
enced by platelet counts, is 10-fold higher in controls
than in PCSV patients.
Conclusions
This preliminary study suggests that patients who
experience vasodilatation after cardiac surgery may have
a preoperative AVP system stimulation that results in a
relative postoperative deficiency. Future trials are needed
to confirm the possible relationship between the
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Figure 2 Correlation analysis between arginine vasopressin
and copeptin plasma concentrations. A Spearman rank-order
correlation test has been performed to assess the correlation
between arginine vasopressin (AVP) and copeptin plasma
concentrations from 191 pairs of measurements. Spearman r = 0.76,
P < 0.001.
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copeptin, and AVP store depletion.
Key messages
￿ Copeptin plasma concentration is increased before
CPB in patients experiencing PCSV.
￿ Copeptin is a marker of cardiac failure intensity,
which may be useful to identify patients at risk of
post cardiac surgery vasoplegia.
￿ Increased stimulation of the vasopressin system
before surgery may contribute to vasopressin defi-
ciency after surgery.
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